Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
  • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
  • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
  • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
  • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
  • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/189—Enzymes
• • C—CHEMISTRY; METALLURGY
  • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
  • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
  • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
  • C11D3/16—Organic compounds
  • C11D3/38—Products with no well-defined composition, e.g. natural products
  • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Y—ENZYMES
  • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
  • C12Y304/21—Serine endopeptidases (3.4.21)

Definitions

• the present invention relates to the field of proteases. Background
• Proteases are today used in large array of industrial applications, including animal feed, detergents, fruit and beverage processing, leather processing, production of protein hydrolysates, hard surface cleaning or biofilm cleaning, treatment of necrotic or burned tissue to promote wound healing and/or food preparation including baking dough preparation.
• thermostability helps to increase the processability of the respective protease, because the latter oftentimes undergoes thermal treatment during the manufacturing process.
• the feed is often subjected to heat, e.g., by application of steam, to reduce or eliminate pathogens, increase storage life of the feed and optimized utilization of the ingredients leading to improved feed conversion.
• the conditioning time can vary from a few seconds up to several minutes depending on the type and formulation of the feed.
• the temperature during conditioning typically ranges from 70°C to 100°C.
• the feed is sometimes extruded through a pelleting die, which for a short time raises the temperature of the feed incrementally due to heat dissipation caused by friction.
• protease enzymes are exposed to heat as well. This includes the use in detergents (e.g. exposure to hot water during laundry washing), fruit and beverage processing (heat exposure during the squeezing process or due to pasteurization or sterilization), leather processing, production of protein hydrolysates, hard surface cleaning or biofilm cleaning, treatment of necrotic or burned tissue to promote wound healing, processing aid in tissue engineering (sterilization, and denaturation of prion proteins) and/or food preparation including baking dough preparation.
• detergents e.g. exposure to hot water during laundry washing
• fruit and beverage processing heat exposure during the squeezing process or due to pasteurization or sterilization
• leather processing production of protein hydrolysates
• hard surface cleaning or biofilm cleaning treatment of necrotic or burned tissue to promote wound healing
• processing aid in tissue engineering sterilization, and denaturation of prion proteins
• food preparation including baking dough preparation.
• proteases are proteins, they are susceptible to denaturation by heat and pressure. Denaturing essentially alters the structure of the enzyme, resulting in decreased activity levels and decreased efficacy of the enzyme.
• Post-pellet liquid application which is relatively complex and expensive because it requires the purchase and installation of specialized equipment, space in which to store the liquid enzyme and careful calculation of the amount of enzyme to apply.
• Another option is the application of a protective coating before pelleting of the protease with other ingredients (e.g., in feed or detergents).
• This approach may reduce the efficacy of the enzyme because the coating may not fully dissolve, e.g., in the washing medium, or in the digestive tract of the animal. It is furthermore difficult to achieve a coating design that can withstand the high heat and moisture content of the pelleting process, but subsequently dissolve in the lower temperature and higher moisture conditions, e.g., in the animal's gut or the washing machine.
• proteases are derived from thermophilic and hyper-thermophilic organisms and have unique structure and function properties of high thermostability.
• these proteases may suffer from other limitations, like suboptimal activity, specificity, bioavailability, pH-range or processability. It is hence one object of the present invention to provide stable protease variants which do not suffer from the above discussed limitations.
• embodiments disclosed herein are not meant to be understood as individual embodiments which would not relate to one another.
• Features discussed with one embodiment are meant to be disclosed also in connection with other embodiments shown herein. If, in one case, a specific feature is not disclosed with one embodiment, but with another, the skilled person would understand that does not necessarily mean that said feature is not meant to be disclosed with said other embodiment. The skilled person would understand that it is the gist of this application to disclose said feature also for the other embodiment, but that just for purposes of clarity and to keep the specification in a manageable volume this has not been done.
• a protease variant which is at least 90% identical to the full length amino acid sequence of a Kumamolisin AS backbone as set forth in any of SEQ ID NOs 1 - 3, or a fragment, fraction or shuffled variant thereof maintaining proteolytic activity.
• the protease variant demonstrates altered or improved stability compared to
• shuffled variant relates to a combination of such fragment or fraction with one or more fragments from other homologous enzymes, as long as such combination maintains proteolytic activity.
• homologous enzyme describes enzymes belonging to the same structural fold as Kumamolisin and at least 40% sequence identity. This category encompasses Sedolisins as discussed below herein.
• the Kumamolisin AS variant according to the invention has 93 % identity, more preferably 95 % identity, more preferably 98 % identity, most preferably 99 % identity.
• Keramolisin refers to acid proteases from the Sedolisin family of peptidases, also called S53 (MEROPS Accession MER000995, see also Wlodawer et al, 2003), comprising acid-acting endopeptidases and a tripeptidyl-peptidase.
• Sedolisins are endopeptidases with acidic pH optima that differ from the majority of endopetidases in being resistant to inhibition by pepstatin (Terashita et al, 1981; Oda et al, 1998).
• the activation of sedolisins involves autocatalytic cleavage at pH below pH 6.5, better below pH 3.5 (see also patent application EP16176044 and Okubo et al, 2016), which releases one or more peptides to deliver the maturated and active form. Said autocatalytic cleavage is inhibited under alkaline, neutral and lightly acidic conditions.
• Sedolisins comprise a catalytic triad with Glu, Asp and Ser, which in Kumamolisin AS according to SEQ ID NO 1 reside in positions Glu267, Asp271 and Ser278.
• the Ser residue is the nucleophile equivalent to Ser in the catalytic triad Asp, His, Ser triad of subtilisin proteases (MEROPS family S8), and the Glu of the triad is a functional substitution for the His general base in subtilisin though not in structural equivalent positions.
• sedolisins The protein folds of sedolisins are clearly related to that of subtilisin, and both groups are sometimes called serine proteases. However, sedolisins have additional loops. The amino acid sequences are not closely similar to subtilisins, and this, taken together with the quite different active site residues and the resulting lower pH for maximal activity, justifies the separate families.
• a protease variant which comprises an amino acid sequence derived from a Kumamolisin AS as set forth in SEQ ID NO. 1, or a fragment, fraction or shuffled variant thereof maintaining proteolytic activity, which protease variant has one or more amino acid substitutions at one or more residue positions in SEQ ID NO.
• the claimed protease can be a fragment, fraction or shuffled variant thereof maintaining proteolytic activity.
• the resulting amino acid sequence is shorter than that of SEQ ID NO 1 or 4
• the numbering of the mutant residues still refers to the full length SEQ ID NO 1 or 4, and has to be translated respectively to the numbering of the shorter form.
• the protease variant demonstrates altered or improved stability compared to
• the protease variant has at least one amino acid substitution selected from the group consisting of D447S, A449Y, A517T, N510H, E360L, E360V, E360C, V502C, E453W, A514T, A514Y, A514D, A514S, A460W, A386I, A392V, A392L, A392I, A392M, T301S, D199E, Q518G, P553K, E269M, E269T, E269C, E269H, E269Q, G266A, D293Y, G320A, R412Q, E421R, A487Q, T461V, T461C, A331F, A331Y, A329Q, A329H, A329T, S435I, S435R, S435T, S435V, V274I, A372S, K283L
• the claimed protease can be a fragment, fraction or shuffled variant thereof maintaining proteolytic activity. In such case, the resulting amino acid sequence is shorter, or longer, than that of SEQ ID NO 1 or 4, while the numbering of the mutant residues still refers to the full length SEQ ID NO 1 or 4.
• the protease variant has at least one amino acid substitution compared to the Kumamolisin AS as set forth in SEQ ID NO 1 or 4, which substitution is selected from the group consisting of:
• substitutions cause a high ⁇ 50 when introduced individually into the Kumamolisin AS as set forth in SEQ ID NO 1 or 4, and are therefore preferred, while others have a high occurrence in the combinatorial and distinct clones of Tables 2a, 2b and 4 and some combinations, which have a combination of individual substitutions with a high overall ⁇ 50.
• protease inhibitors sey bean Bowman-Birk and Kunitz-type trypsin and/or chymotrypsin inhibitors
• pH profile pH and pepsin stability
• stability against and performance under higher ionic strength like fermentation titers
• the claimed protease can be a fragment, fraction or shuffled variant thereof maintaining proteolytic activity.
• the resulting amino acid sequence is shorter than that of SEQ ID NO 1 or 4
• the numbering of the mutant residues still refers to the full length SEQ ID NO 1 or 4.
• the protease variant has at least two amino acid substitutions compared to the Kumamolisin AS backbone as set forth in SEQ ID NO 1 or 4.
• the protease variant has at least three, more preferably at least four, more preferably at least five and most preferably at least six amino acid substitutions selected from said group.
• these amino acid substitutions are combinations of the individual substitutions discussed above.
• the protease variant has at least two amino acid substitutions compared to the Kumamolisin AS backbone as set forth in SEQ ID NO 1 or 4, the at least 2 amino acid substitutions being at two or more residue positions in SEQ ID NO 1 or 4 selected from the group consisting of 447 and 449, 453, 502, 510, 517, 360, 460, 199, 266, 301, 386 and 514.
• the protease variant has at least three, more preferably at least four, more preferably at least five and most preferably at least six amino acid substitutions selected from said group.
• the protease variant has at least one, preferably at least two, more preferably at least three, more preferably at least four, more preferably at least five, most preferably at least six amino acid substitutions selected from the group consisting of D447S, A449Y, A517T, N510H, E360L, E360V, E360C, V502C, E453W, A514T, A514Y, A460W, A386I, D199E, G266A, T301S.
• Tables 2a, 2b and 4 show sets of such so-called “distinct clones” or “combinatorial clones” which have combinations of the individual mutations set forth above.
• combinatorial clone or variant means a clone or variant screened from a recombination library. Such a recombination library contains a population carrying different amounts and mutations selected from the group of table 1.
• the term "distinct clone or variant” means A clone constructed containing a defined set of mutations selected from the group of table 1 in a rational approach.
• said improved stability which the protease variant according to the invention has is improved thermostability (IT50).
• the thermostability of an enzyme is usually determined by measuring the inactivation temperature (IT 50).
• the "inactivation temperature” is defined as the temperature at which the residual activity of the enzyme after incubation for a certain duration and subsequent cooling to room temperature is 50% of the residual activity of the same enzyme incubated for the same duration under the same conditions at room temperature.
• the protease variant has a set of substitutions at selected residues in the Kumamolisin AS backbone as set forth in SEQ ID NO 1 or 4, which set is at least one of the following a) 360, 447, 449 and 510
• said improved stability is improved thermostability (IT50) of either the activated enzyme or the zymogen.
• IT50 thermostability
• the protease variant has an IT50 of between > 75 and ⁇ 105 °C.
• an IT50 of between > 70 and ⁇ 90°C is provided, while a for the zymogen an IT50 of between > 80 and ⁇ 105°C is provided.
• the different variants are either characterized by their IT50, or by ⁇ 50 (i.e., the difference compared to the wildtype IT50).
• a nucleic acid molecule encoding a protease variant according the above description is provided. Furthermore, a plasmid or vector system comprising said nucleic acid molecule is provided, as well as a host cell being transformed with said plasmid or vector and/or comprising said nucleic acid molecule is provided. Further, a method for producing a protease or protease variant is provided, said method encompassing: a) cultivating said host cell, and
• composition comprising a protease variant according to the above description is provided, which composition has a pH of > 5.
• composition is generally discussed - yet not with the specific protease variants disclosed herein - in EP application No 16176044.2-1375 and later applications claiming the priority thereof, the content of which is incorporated by reference herein.
• a feed additive, feed ingredient, feed supplement, and/or feedstuff comprising a protease variant or a composition according to the above description is provided.
• feed additive feed ingredient, feed supplement, and/or feedstuff is preferably meant for monogastric poultry, pig, fish and aquaculture, where it helps to increase protein digestion and absorbance from the feedstuff, plus degrade proteinogenic compounds which are detrimental for animal health or digestion.
• protease for at least one purpose or agent selected from the group consisting of:
• an additive, ingredient or agent for one purpose or agent selected from the group consisting of:
• a process of generating a protease variant according to the above description comprises: i) mutagenizing a DNA, cDNA or mR A encoding a Kumamolisin AS amino acid sequence as set forth in any of SEQ ID NOs 1 - 4
• the encoding nucleic acid sequence and/or the amino acid sequence of one or variants of Kumamolisin AS is determined.
• routine methods from the prior art can be used.
• SEQ ID NO 1 shows the proenzyme (propeptide plus enzyme, also called zymogen herein) sequence of the Kumamolisin AS backbone used herein. It is important to understand that, while the wildtype sequence of Kumamolisin AS has an N-terminal M residue, the Kumamolisin AS backbone used herein lacks said M, because the latter was replaced by a signal sequence that was later cleaved off. Such signal sequence is for example.
• the propeptide hence comprises AAs 2 - 189 (former N-terminal M which is lacking is yet considered as AA NO 1 in the numbering of SEQ ID NO), and the enzyme comprises AAs 190 - 553:
• LQALLPSASQ PQP 553 The propeptide is shaded in grey.
• the sacB leader sequence comprises AAs 1 - 29 (wavy underline) and replaces the original N-terminal M of the propeptide.
• the propeptide (shaded in grey) comprises AA 30 - 217, the activated enzyme comprises AA 218 - 581 and the His-tag comprises AAs 582 - 587 (double underline).
• SEQ ID NO 4 shows the proenzyme (propeptide plus enzyme) sequence of the Kumamolisin AS wildtype, as obtained from Alicyclobacillus sendaiensis (GenBank: AB085855.1).
• SEQ ID NO 4 differs from SEQ ID NO 1 , which shows the sequence of the Kumamolisin AS backbone used herein in that the latter lacks the N-terminal M still present in the Wildtype SEQ ID No 4. This is because the N-terminal M was replaced, in SEQ ID No 1 , by the sacB signal sequence, which was later cleaved off.
• the propeptide comprises AAs 1 - 189
• the enzyme comprises AAs 190 - 553:
• Fig. 1 shows the distribution of mutations in variants optimized for thermal stability of the zymogen and the activated enzyme.
• Fig. 2 shows the effects of the ionic strength on stability and performance for the WT and top variants #1 to #7 from table 4.
• Fig. 3 - 5 show the occurrence of substitutions at AA position in different sets of distinct clones and combinatorial clones.
• Example 1 Protease activity assay
• Assay buffer 200 niM Sodium Acetate, 1 mM CaCl 2 , 0,01 % Triton X- 100 at pH 3
• Substrate stock solution 100 mM in water free DMSO
• Substrate working solution Substrate Stock solution diluted 1 :50 in assay buffer,
• Execution Load 50 of the diluted sample into the wells of a Nunc 96 clear flat bottom plate. Dilution is made in water containing 0.01% Triton-XlOO corresponding to the volumetric activity of the sample. Start reaction by adding 50 of substrate working solution. Measure kinetics at 37°C by monitoring the increase in adsorption at 410 nm as a measure for enzymatic activity. The activity was calculated by building a calibration curve with a reference enzyme preparation of the backbone with known proteolytic activity measured by a reference method.
• IT50 defines the temperature where 50% of the activity is inactivated under the conditions described above. Although not equivalent to, it is a measure for the thermal stability in the application, e.g. pelleting conditions or conditions in a detergent application, either dish washing or the cleaning of a fabric or hard surface and other technical applications.
• Assay buffers 50 mM sodium phosphate, 0,25mM CaCl 2 pH6.5
• Thermal inactivation execution Samples were diluted corresponding to the volumetric activity in potassium phosphate buffer. The pH of the final solution was checked to be above pH 6.3. The samples were transferred in replicates, 20 per well, into a 384 well PCR plate according to the direction of the temperature gradient of the PCR machine. The plates were sealed with an adhesive or hot melting cover foil and incubated on a thermal gradient cycler with a temperature gradient of +/- 12 °C around the expected IT50 value for 10 minutes. The samples were cooled to 8°C before measuring the residual activity of the samples with AAPF-pNA as followed.
• Enzyme activation prior to thermal inactivation execution Samples were diluted corresponding to the volumetric activity in glycine buffer pH 2.8 as described in 2b) and pH was checked to be equal or lower than pH 4.0. Samples were activated by an incubation for 1 hour at 37°C. After the incubation pH was set to above 7.0 by diluting the samples 1 :3 in 50 mM sodium phosphate buffer pH 8.0. Thermal inactivation of activated enzyme protein execution. Aliquots of the activated enzyme protein were transferred in replicates, 20 ⁇ ⁇ per well, into a 384 well PCR plate according to the direction of the temperature gradient of the PCR machine.
• the plates were sealed with an adhesive or hot melting cover foil and incubated on a thermal gradient cycler with a temperature gradient of +/- 12 °C around the expected IT50 value for 10 minutes.
• the samples were cooled to 8°C before measuring the residual activity of the samples with AAPF-pNA as followed.
• Samples, 15 each from the temperature incubation plate were transferred into a 384 well greiner clear flat bottom PS-microplate and 9 of glycine/HCl buffer was added to adjust the pH to 3.0.
• the assay was started by adding 24 ⁇ , of an AAPF- pNA solution (2 mM AAPF-pNA in water with 0.01% Triton-XlOO) and activity was measured by following the kinetics at 37°C.
• the normalized experimental data for residual activity at the inactivation temperatures were fitted to a four parameter logistics function to evaluate the IT50.
• Undiluted bacterial supernatant containing enzyme protein was titrated with 1 M HC1 to pH 2.5. 90 ⁇ were then transferred to a Nunc 96-well clear flat bottom microtiter plate. 10 ⁇ of a 250 ⁇ g/mL Pepsin stock solution in pH 2.5 buffer (final concentration in assay 25 ⁇ g/mL) or pH 2.5 buffer were added to each well and then incubated at 37°C for 30 min. Finally, 5 ⁇ of a 100 ⁇ Pepstatin A solution (final concentration 5 ⁇ ) was added to each well to stop the pepsin reaction. 25 ⁇ of the sample were transferred in 175 ⁇ glycine/HCl buffer pH 3.0 in a new Nunc 96-well clear flat bottom microtiter plate.
• BBI/KTI Bowman-Birk and Kunitz-type inhibitors
• BBI/KTI Bowman-Birk and Kunitz-type inhibitors
• the assay principle is that a proteolytic degradation of the BBI/KTI by protease activity recovers the natural trypsin activity on Benzyl-Arginine-pNA (Bz-R-pNA) substrate without inhibitors.
• 90 ⁇ ⁇ of bacterial supernatant containing enzyme protein was diluted in glycine/HCl buffer to pH 3.0 and then incubated at 37°C for 30 min.
• 20 ⁇ of the sample was then mixed with 20 ⁇ inhibitor solution (KTI: 8 ⁇ g/mL; BBI: 16 ⁇ g/mL; KTI/BBI: 4/8 ⁇ g/mL diluted in glycine buffer pH 3.0) and further incubated at 37°C for 60 min.
• 20 ⁇ inhibitor solution KTI: 8 ⁇ g/mL; BBI: 16 ⁇ g/mL; KTI/BBI: 4/8 ⁇ g/mL diluted in glycine buffer pH 3.0
• 15 ⁇ of the sample were transferred into a 384-well Greiner flat bottom PS-microplate and then 15 ⁇ trypsin solution in pH 8.0 (final trypsin concentration 1 ⁇ g/mL; final pH 7.0 or pH 7.5) was added to each well and the plate was incubated at 37°C for 10 min.
• Methods to mutagenize a protein like an enzyme, to obtain a library of mutated proteins members of which may have altered characteristics, are well established.
• Methods to mutagenize a protein encompass site directed mutagenesis and others, as described e.g. in Hsieh & Vaisvila (2013), content of which incorporated herein by reference for enablement purposes.
• the generated genetic diversity either in the initial stage in form of single site saturation libraries or in the subsequent stage in the form of recombination libraries or distinct clones was screened for variants with an optimized phenotype, i.e. increased thermal stability using the method as described in example lb) with adaptations required to run them in a fully automated robotic workstation at high throughput.
• Protease variants were derived which differed in one or more amino acid positions from SEQ ID NO 2, including two positions, three positions, n positions. Appropriate iterative rounds of the procedures described herein were performed to satisfy the demands of the application
• the following individual mutations which increase the IT50 compared to the used backbone were identified.
• Distinct variants were generated by introducing selected distinct mutations into the Kumamolisin AS wild-type sequence via site-directed mutagenesis. Suitable mutagenic PCR methods known in the art and standard cloning techniques as described in Green & Sambrook (eds), Molecular Cloning, 4 th edition, CSHL were used. Protease enzyme variants were characterized after heterologous expression in Bacillus subtilis and phenotypically analysis using the methods described above.
• Combinatorial libraries combining mutations identified in the examples provided above and outlined in Table 1 were generated by well-known PCR methods as described in Yolov and Shabarova (1990) and standard cloning techniques as described in Green & Sambrook (eds), Molecular Cloning, 4th edition, CSHL were used. Combinatorial libraries were screened for optimized variants as described in example 3.
• the IT50 of the backbone was determined in the same experiment as the variant the measured IT50 of the backbone can be slightly different from the average value. Results are shown in the following Table 2a (Fig. 3 shows results in graphic form):
• Table 2a Distinct clones comprising selected combinations of mutations from table 1, and their ⁇ 50 compared to the wildtype # Mutations i n distinct clones and selected combinatorial clones
• Table 2a ctd' Distinct clones comprising selected combinations of mutations from table
• Table 2a ctd' Distinct clones comprising selected combinations of mutations from table
• Table 2a ctd' Distinct clones comprising selected combinations of mutations from table
• Table 2a ctd' Distinct clones comprising selected combinations of mutations from table
• Table 2a ctd' Distinct clones comprising selected combinations of mutations from table
• the mutations can have positive or negative effects on other enzyme parameters, as the producibility in fermentative microbial production systems or the stability against pH- conditions or endogenous proteases of the animal, like pepsin.
• Testing the stability of feed enzymes at low pH and in the presence of pepsin is a standard for feed enzymes and was performed in this study as outlined in example le.
• the stability against higher ionic strength is not a standard test for feed enzymes though high ion concentrations can interfere with the enzyme stability and with the enzyme performance under such conditions and can be found for example in the gut.
• the secretion of acid in the gut and the feed ingredients translate to an increased ionic strength.
• Fig. 2 shows that the wildtype suffers from combined effects of stability and performance reduction in the presence of higher ionic strength.
• Fig. 2 also shows the effect of ionic strength on the top variants also shown in table 4, variants #1 to #7.
• the performance and stability in high ionic strength was tested as described in example Id.
• the pH profile was a control parameter and tested as described in example If.
• the digestion of proteinaceous antinutritive factors like the Trypsin/chymotrypsin inhibitors BBI and KTI Boman-Birk inhibitors and Kunitz-type inhibitors
• Kunitz-type inhibitors is a potential beneficial performance characteristic of a protease which was tested as described in example lg.
• Table 4 describes the variants consolidating a multitude of performance and stability parameters (Fig. 5 shows results in graphic form).
• Table 4 All variants shown in table 4 are better or equally well produced in a microbial production system than the wildtype and have no relevant changes in their pH activity profile tested as described in example Id. Table 4 ranks these variants based on the thermal stability of the activated enzyme, the pH/pepsin stability and the stability against and the performance under higher ionic strength.
• Table 4 Some distinct and combinatorial clones with particularly good performance
• Table 5 shows the frequency of occurrence of given mutations preferred combinatorial and distinct variants. The frequency of occurrence is a measure for the role and importance of a given mutation.
• Table 5 Frequency of occurrence of given mutations in preferred combinatorial and distinct variants. Frequency of occurrence is a measure for the role and importance of a given mutation.
• Table 6 shows the impact of single mutations on ⁇ 50 of the zymogen or the activated form. Again, the amount of impact of a single mutation on ⁇ 50 is a measure for the role and importance of a said mutation.
• Table 7 shows a set of variants based on variant #1 of Table 7. In the course of engineering the mutations at position 502 and 510 seemed to change the activity at extrem acidic pH, below pH 2.
• Excluding mutations at 502 and 510 reduced the thermostability significantly below the targeted temperature stability for the activated enzyme, as for example in Table 7, clone #2 which has a 7,8°C reduction in thermal stability compared to clone #1.
• a set of distinct variants were constructed by a rational approach taking advantage of the mutations identified and shown in Tables 1 and 6 to compensate for the effect of 502 and 510. With the exception of D399S substitutions can gradually or fully compensate the effect of mutations at 502 and 510.

Landscapes

• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Genetics & Genomics (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Health & Medical Sciences (AREA)
• Biochemistry (AREA)
• General Engineering & Computer Science (AREA)
• Polymers & Plastics (AREA)
• Biomedical Technology (AREA)
• Medicinal Chemistry (AREA)
• Biotechnology (AREA)
• Molecular Biology (AREA)
• Microbiology (AREA)
• Food Science & Technology (AREA)
• Animal Husbandry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Enzymes And Modification Thereof (AREA)
• Detergent Compositions (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Fodder In General (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)

Priority Applications (13)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=57629395

Family Applications (1)

Country Status (10)

Cited By (1)

Families Citing this family (1)

Citations (1)

Family Cites Families (4)

• 2017
  • 2017-12-22 AU AU2017380106A patent/AU2017380106B2/en active Active
  • 2017-12-22 CA CA3047868A patent/CA3047868A1/en active Pending
  • 2017-12-22 US US16/471,507 patent/US11396648B2/en active Active
  • 2017-12-22 KR KR1020237022708A patent/KR102686572B1/ko active Active
  • 2017-12-22 WO PCT/EP2017/084452 patent/WO2018115473A2/en not_active Ceased
  • 2017-12-22 BR BR112019012980-4A patent/BR112019012980A2/pt unknown
  • 2017-12-22 JP JP2019555724A patent/JP7035079B2/ja active Active
  • 2017-12-22 MX MX2019007287A patent/MX2019007287A/es unknown
  • 2017-12-22 CN CN201780087051.4A patent/CN110325636A/zh active Pending
  • 2017-12-22 KR KR1020197020123A patent/KR102553627B1/ko active Active
  • 2017-12-22 EP EP17835479.1A patent/EP3559225A2/en active Pending
• 2019
  • 2019-06-19 MX MX2024000078A patent/MX2024000078A/es unknown
• 2022
  • 2022-03-02 JP JP2022031591A patent/JP7344329B2/ja active Active
• 2024
  • 2024-04-17 AU AU2024202526A patent/AU2024202526A1/en active Pending

Patent Citations (1)

Non-Patent Citations (7)

Also Published As

Similar Documents

Legal Events